iRegene Therapeutics has received RMAT designation from the US FDA for its lead product NouvNeu001 for the treatment of Parkinson's disease.[1][2][3] NouvNeu001 is the first chemically induced allogeneic dopaminergic neuronal precursor cell derived from induced pluripotent stem cells (iPSC).[1][2] This therapy replaces the missing dopaminergic neurons, restores damaged neural circuits and supports the natural production of dopamine in the patient's body.[1][2][3] It is the first iPSC-derived allogeneic cell therapy in the world to receive both Fast Track Designation (FTD) in August 2025 and RMAT from the FDA.[2][3] Data from phase I clinical trials showed a significant improvement in MDS-UPDRS Part III scores for motor function.[3] NouvNeu001 is currently in global phase II clinical trials and represents a disease-modifying therapy.[1][2][6] RMAT designation allows for earlier cooperation with the FDA and potentially accelerated approval.[3]